SNSS - Sunesis Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.7691
-0.0638 (-7.66%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.8329
Open0.8300
Bid0.7901 x 1400
Ask0.8400 x 1000
Day's Range0.7691 - 0.8499
52 Week Range0.2000 - 2.2600
Volume208,448
Avg. Volume1,021,996
Market Cap55.781M
Beta (3Y Monthly)4.53
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire

    Sunesis Pharmaceuticals Reports Second Quarter 2019 Financial Results and Recent Highlights

    SOUTH SAN FRANCISCO, Calif., Aug. 07, 2019 -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the quarter ended June 30, 2019. Loss from.

  • GlobeNewswire

    Sunesis Pharmaceuticals to Host Conference Call on August 7th to Discuss Second Quarter 2019 Financial Results and Recent Highlights

    SOUTH SAN FRANCISCO, Calif., July 31, 2019 -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Wednesday, August 7th, 2019 at.

  • GlobeNewswire

    Sunesis Announces Pricing of $25 Million Offering of Securities

    Sunesis Pharmaceuticals, Inc. (SNSS) today announced the pricing of underwritten public offerings of (i) 33,333,667 shares of its common stock and (ii) 8,333 shares of its non-voting Series F Convertible Preferred Stock (“Series F Stock”).  The public offering price of each share of common stock is $0.60 and the public offering price of each share of Series F Stock, convertible into 1,000 shares of common stock, is $600. Sunesis expects to receive combined gross proceeds of approximately $25 million from these offerings, before deducting the underwriting discounts and other estimated offering expenses. Sunesis has granted the underwriters a 30 day option to purchase up to an additional 5,000,050 shares of common stock to cover over-allotments, if any.

  • GlobeNewswire

    Sunesis Announces Proposed Public Offering of Common Stock and Preferred Stock

    Sunesis Pharmaceuticals, Inc. (SNSS) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and Series F Convertible Preferred Stock in underwritten public offerings. There can be no assurance as to whether or when the proposed offerings may be completed, or as to the actual size or terms of the offerings.  Sunesis also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the public offering to cover over-allotments, if any.  Sunesis anticipates using the net proceeds from the proposed offerings to fund ongoing development of vecabrutinib, ongoing research and development, and general corporate purposes.

  • GlobeNewswire

    Sunesis Pharmaceuticals Announces Executive Promotions and Provides Clinical Update

    Sunesis Pharmaceuticals, Inc. (SNSS) today announced the promotion of Judy Fox, Ph.D. from Chief Scientific Officer, Senior Vice President to Chief Scientific Officer, Executive Vice President, Research & Development and the promotion of Parvinder (Par) S. Hyare from Vice President, Global Oncology Operations to Senior Vice President, Commercial. Dr. Fox received her Ph.D. in Biological Chemistry from the Massachusetts Institute of Technology, and an A.B. in Chemistry from Bryn Mawr College.

  • GlobeNewswire

    Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at EHA Annual Meeting

    Sunesis Pharmaceuticals, Inc. (SNSS) today announced the presentation of results from the Company’s Phase 1b/2 clinical trial of its non-covalent BTK inhibitor vecabrutinib in adults with relapsed/refractory chronic lymphocytic leukemia (CLL) and other B-cell malignancies. The results are being presented today, June 15, from 5:30-7:00 p.m. CET in a poster session titled “Chronic lymphocytic leukemia and related disorders – Clinical” at the 24th Congress of the European Hematology Association (EHA) in Amsterdam. The poster, titled “Preliminary Results of a Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton’s Tyrosine Kinase Inhibitor (BTKi) Vecabrutinib in B-Cell Malignancies,” Abstract No. PS1148, is available at www.sunesis.com.

  • GlobeNewswire

    Sunesis Pharmaceuticals Reports First Quarter 2019 Financial Results and Recent Highlights

    Phase 1b/2 Trial of Vecabrutinib Advances into 200 mg Cohort Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif., May 08, 2019 --.

  • GlobeNewswire

    Sunesis Pharmaceuticals to Host Conference Call on May 8th to Discuss First Quarter 2019 Financial Results and Recent Highlights

    Sunesis Pharmaceuticals, Inc. (SNSS) today announced that it will host a conference call on Wednesday, May 8th, 2019 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the first quarter ended March 31, 2019. To access the live audio webcast, or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at http://ir.sunesis.com. The webcast will be recorded and available for replay on the company's website for two weeks.

  • GlobeNewswire

    Sunesis Pharmaceuticals Announces Refinancing of Existing Loan with $5.5 Million Loan from Silicon Valley Bank

    Sunesis Pharmaceuticals, Inc. (SNSS) today announced that it has entered into a $5.5 million loan agreement with Silicon Valley Bank. The new agreement allows the company to retire its existing loan and defer any principal repayment on the new loan for more than 18 months. The new facility includes interest-only payments through 2020, with principal repayment over 24 months beginning in 2021, as well as a lower interest rate than the previous loan.

  • ACCESSWIRE

    Four Healthcare Stocks Heating Up on Thursday

    This predicted growth is an indicator that more people will soon need access to quality medical care and the healthcare sector must be aptly prepared. As the healthcare sector continues to progress into the future, investors interested in potentially lucrative opportunities could benefit from focusing on this sector. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Shineco Inc (TYHT), Tonix Pharmaceuticals Holding Corp (TNXP), and Sunesis Pharmaceuticals Inc (SNSS) are 4 healthcare companies worth keeping on your radar.

  • GlobeNewswire

    Sunesis Pharmaceuticals to Present at 18th Annual Needham & Company Healthcare Conference

    Sunesis Pharmaceuticals, Inc. (SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice President, Finance and Corporate Development of Sunesis, will present at the Needham & Company 18th Annual Healthcare Conference on Wednesday, April 10, 2019 at 2:10 PM Eastern Time at the Westin Grand Central Hotel in New York City. Sunesis has built an experienced drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase inhibitor pipeline, with an emphasis on its oral non-covalent BTK inhibitor vecabrutinib.

  • ACCESSWIRE

    Edison Issues Outlook on Sunesis Pharmaceuticals (SNSS)

    LONDON, UK / ACCESSWIRE / March 22, 2019 / Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) is currently in the dose-escalation portion of the Phase Ib/II study of its BTK inhibitor vecabrutinib, and the first ...

  • GlobeNewswire

    Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights

    SOUTH SAN FRANCISCO, Calif., March 07, 2019 -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the fourth quarter and year ended December 31,.

  • GlobeNewswire

    Sunesis Pharmaceuticals to Participate in Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., March 04, 2019 -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Company will participate in three upcoming investor.

  • GlobeNewswire

    Sunesis Pharmaceuticals to Host Conference Call on March 7th to Discuss Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights

    Sunesis Pharmaceuticals, Inc. (SNSS) today announced that it will host a conference call on Thursday, March 7th, 2019 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the fourth quarter and year ended December 31, 2018. To access the live audio webcast, or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at http://ir.sunesis.com. The webcast will be recorded and available for replay on the company's website for two weeks.

  • GlobeNewswire

    Sunesis Announces Pricing of $20 Million Offering of Securities

    Sunesis Pharmaceuticals, Inc. (SNSS) today announced the pricing of underwritten public offerings of (i) 23,000,000 shares of its common stock and (ii) 17,000 shares of its non-voting Series E Convertible Preferred Stock (“Series E Stock”).  The public offering price of each share of common stock is $0.50 and the public offering price of each share of Series E Stock, convertible into 1,000 shares of common stock, is $500. Sunesis has granted the underwriters a 30 day option to purchase up to an additional 3,450,000 shares of common stock to cover over-allotments, if any.

  • GlobeNewswire

    Sunesis Pharmaceuticals Announces Advancement into 100mg Cohort of Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies

    Sunesis Pharmaceuticals, Inc. (SNSS) today announced that the Company has opened the 100 mg cohort in the Phase 1b/2 trial of its non-covalent BTK inhibitor vecabrutinib in adults with relapsed/refractory chronic lymphocytic leukemia (CLL) and other B-cell malignancies. “Thus far, we have seen an encouraging safety profile, evidence of pharmacodynamic activity in CLL and other B cell cancer patients both with and without BTK C481 mutations, and some improvements in clinical symptoms. Vecabrutinib (SNS-062) is a selective, oral, reversible, non-covalent inhibitor of Bruton's tyrosine kinase (BTK).

  • GlobeNewswire

    Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at ASH Annual Meeting

    Sunesis Pharmaceuticals, Inc. (SNSS) today announced the presentation of results from the Company’s Phase 1b/2 clinical trial of its non-covalent BTK inhibitor vecabrutinib in adults with relapsed/refractory chronic lymphocytic leukemia (CLL) and other B-cell malignancies. The results will be presented today, December 2, from 6:00-8:00 p.m. PT in a poster session titled “CLL: Therapy, excluding Transplantation: Poster II” at the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, California. “To date, vecabrutinib has demonstrated both an encouraging safety profile and evidence of pharmacodynamic activity in CLL and other B cell cancer patients both with and without the BTK C481 mutation,” said Dayton Misfeldt, Sunesis interim Chief Executive Officer.

  • GlobeNewswire

    Sunesis Pharmaceuticals to Provide Program Update for Non-Covalent BTK-Inhibitor Vecabrutinib at Analyst & Investor Event during ASH 2018

    Sunesis Pharmaceuticals, Inc. (SNSS) today announced it will provide a program update for vecabrutinib, the Company’s oral, reversible, non-covalent, BTK inhibitor which is currently being evaluated in an ongoing Phase 1b/2 clinical trial in adults with relapsed chronic lymphocytic leukemia (CLL) and other B-cell malignancies. Sunesis’ executive management team will present an update on vecabrutinib from the ongoing Phase 1b/2 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of vecabrutinib in B-lymphoid malignancy patients with prior BTK therapy.  The Phase 1b/2 trial is an open-label, sequential-group study that is enrolling patients across eight leading sites in the United States.

  • GlobeNewswire

    Sunesis Pharmaceuticals to Present at the 30th Annual Piper Jaffray Healthcare Conference

    Sunesis Pharmaceuticals, Inc. (SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice President, Finance and Corporate Development of Sunesis, will present at the 30th Annual Piper Jaffray Healthcare Conference on Wednesday, November 28, 2018 at 7:50 A.M. Eastern Time at the Lotte New York Palace Hotel in New York City. Sunesis has built an experienced drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase inhibitor pipeline, with an emphasis on its oral non-covalent BTK inhibitor vecabrutinib.

  • GlobeNewswire

    Report: Developing Opportunities within NeuroMetrix, Sunesis Pharmaceuticals, Siga Technologies, NexPoint Residential Trust, Frequency Electronics, and Horizon Technology Finance — Future Expectations, Projections Moving into 2018

    NEW YORK, Nov. 15, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire

    Sunesis Pharmaceuticals Reports Third Quarter 2018 Financial Results and Recent Highlights

    Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif., Nov. 05, 2018 -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported.

  • GlobeNewswire

    Sunesis Pharmaceuticals Announces Presentations at 60th American Society of Hematology Annual Meeting

    SOUTH SAN FRANCISCO, Calif., Nov. 01, 2018 -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced two poster presentations and an oral presentation at the 60th.